SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million

"Our collaboration with Castle Biosciences is moving ahead at full speed," said Pia Renaudin, CEO of SciBase. "With this loan, we secure the resources needed to smoothly ramp up production and maintain uninterrupted growth. We expect the resulting improvements in product margins will create value across all markets and indications. This collaboration will also help us accelerate the adoption of Nevisense in skin barrier health and continue driving strong sales growth in skin cancer diagnostics."

STOCKHOLM, 07/11/2025 (informazione.news - comunicati stampa - salute e benessere)

 said , CEO of SciBase.

The loan agreement is a five-year loan amounting to SEK 20 million . The interest rate on the loan amounts to STIBOR plus two (2) per cent and shall be paid quarterly. However, the first interest payment date shall be 31 March 2026 , and the final interest payment date shall be on the repayment date of the loan. The loan shall be repaid in cash no later than five years following the signing of the loan agreement or, if demanded by Castle, by way of conversion of the loan amount into new shares in SciBase. In case of conversion, the conversion price per share shall correspond to the volume weighted average price of the shares in SciBase during the 30 trading days preceding the repayment date. For the avoidance of doubt, repayment of the loan may be made in a combination of cash repayment and conversion repayment. The loan is secured by a share pledge over SciBase's shares in SciBase AB.

Castle Biosciences (NASDAQ: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic treatment decision making for patients with moderate-to-severe atopic dermatitis. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

Pia Renaudin , CEO,
Phone. +46732069802
E-mail: pia.renaudin@scibase.com 

DNB Carnegie Investment Bank AB (publ)
Tel: ++46 8 588 68 570
E-mail: certifiedadviser@carnegie.se

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/scibase/r/scibase-and-castle-biosciences-expand-collaboration-and-license-agreement-and-enter-into-loan-agreem,c4263448

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-and-castle-biosciences-expand-collaboration-and-license-agreement-and-enter-into-loan-agreement-of-sek-20-million-302608427.html